Abstract: The identification apparatus includes a quantitative phase image acquisition unit, a feature quantity extraction unit, a learning unit, a storage unit, and an identification unit. The feature quantity extraction unit extracts a feature quantity of a quantitative phase image of a cell. The learning unit performs machine learning for a quantitative phase image of a known cell of which a type is known based on the feature quantity extracted by the extraction unit. The storage unit stores a result of the machine learning by the learning unit. The identification unit determines, based on the feature quantity extracted by the extraction unit for the quantitative phase image of an unknown cell of which a type is unknown, the type of the unknown cell using the learning result stored by the storage unit.

Abstract: A fluorescence detection device comprises: a plurality of light sources that apply an excitation light from an outside of a living body toward fluorescent dye previously injected into the living body; and a plurality of detectors that detect fluorescence emitted from the fluorescent dye by the excitation light, and output the detected fluorescence as an electric signal. The plurality of light sources and the plurality of detectors are arranged in at least one line. At least one detector is placed between two light sources, and at least one light source is placed between two detectors.

Abstract: The identification apparatus includes a quantitative phase image acquisition unit, a feature quantity extraction unit, a learning unit, a storage unit, and an identification unit. The feature quantity extraction unit extracts a feature quantity of a quantitative phase image of a cell. The learning unit performs machine learning for a quantitative phase image of a known cell of which a type is known based on the feature quantity extracted by the extraction unit. The storage unit stores a result of the machine learning by the learning unit. The identification unit determines, based on the feature quantity extracted by the extraction unit for the quantitative phase image of an unknown cell of which a type is unknown, the type of the unknown cell using the learning result stored by the storage unit.

Abstract: A method is provided for inhibiting proliferation of a high LIX1L-expressing tumor cell, in which the expression or function of a LIX1L gene with respect to a tumor cell highly expressing the LIX1L gene is inhibited.

Abstract: The present invention has an object to measure lymphatic pressure with more safety and ease at lower cost. To achieve this, a lymphatic pressure-measuring system 1 includes: a manchette 11 fitted on a vital observation portion; a measurement unit 13 that measures and outputs pressure of the manchette 11; an infrared camera 21 that detects fluorescence emitted from fluorescent dye previously injected into a lymph vessel in the vital observation portion; and an image processing device 22 that generates and displays an image showing a position of the fluorescent dye in the lymph vessel based on a detection result of the infrared camera 21. The infrared camera 21 repeats the detection while the pressure of the manchette 11 decreases from first pressure to block a lymph flow in the vital observation portion to second pressure at restart of the lymph flow. The measurement unit 13 repeats the measurement during the period.

Abstract: Method, system and device for assisting diagnosis of autism which enable assistance of early detection and early definite diagnosis of autism (especially in infants) based on objective evaluation, using a conventionally suggested “eye-gaze detection technique”. The method for assisting diagnosis of autism of a subject uses an eye-gaze detecting unit, the unit having at least an imaging camera portion. The method includes displaying, at the position in front of the subject along the direction of the eye gaze of the subject, an illusionary image contained in a plane of an illusion-causing image on a displaying device. The eye-gaze position information of the subject looking at the plane is detected, and the eye-gaze position information of the subject is input into an eye-gaze position information storage portion The eye-gaze positions of the subject can be evaluated using a algorithm for assisting diagnosis of autism.

Abstract: A method for diagnosing a risk for preterm delivery or miscarriage in a pregnant woman and preventing preterm delivery or miscarriage in the pregnant woman who has been determined to have the risk is provided. The method includes measuring plasminogen activator inhibitor-1 activity or level in plasma isolated from a pregnant woman. The method also includes determining that the pregnant woman has a risk for preterm delivery or miscarriage when the activity or the level is lower than that in the plasma of a normal pregnant woman. The method also includes administering plasminogen activator inhibitor-1 to the pregnant woman who has been determined to have the risk. A kit for the diagnosis of the degree of risk for preterm delivery or miscarriage also is provided. A pharmaceutical composition for the prevention of preterm delivery or miscarriage, comprising plasminogen activator inhibitor-1, also is provided.

Abstract: An accurate measurement can be made of the light absorbance of deep layer tissue such as in a human body or a fruit. The thickness of fat is computed. A first specific distance and a second specific distance corresponding to the computed fat thickness are computed based a predetermined relationship between the fat thickness, the first specific distance, and measurement sensitivity of a surface layer and measurement sensitivity of a deep layer when light is received at a position the first specific distance away from a light emitting means. A third specific distance and a fourth specific distance are computed corresponding to the computed fat thickness based on a predetermined relationship between the fat thickness, the third specific distance and a measurement sensitivity of an intervening layer and a measurement sensitivity of the deep layer when light is received at a position the third specific distance away from the light emitting means.

Abstract: An object of the present invention is to provide a drug that contains a compound for inhibiting neutral lipid accumulation in cardiovascular tissue or cells and has an excellent prophylactic or therapeutic effect on cardiovascular complications of diabetes. The present invention relates to a prophylactic and/or therapeutic agent for cardiovascular complications of diabetes, the agent containing a compound (preferably a medium-chain fatty acid and/or a medium-chain triglyceride) for inhibiting neutral lipid accumulation.

Abstract: Disclosed is the construction of a system capable of quickly and easily identifying patients having a risk for worsening inflammatory digestive tract disease by identifying a causal factor for the worsening of the inflammatory digestive tract disease. Specifically disclosed is a method for detecting oral bacteria that cause worsening of inflammatory digestive tract disease and/or a screening that targets high risk for worsening of inflammatory digestive tract disease and/or determining the risk for worsening of the inflammatory digestive tract disease by PA not being detected and/or CBP being detected, inclusive of the detection of PA, which is an oral bacteria protein antigen, and/or CBP, which is collagen binding protein, in samples. Also disclosed are a detection reagent and kit used for this method.

Abstract: The present invention enables simple production of osmium tetroxide having comparable performance to that sold in reagents from a solution containing osmium. The present invention relates to a method for producing osmium tetroxide solution, the method comprising a step for using ozone or a similar oxidizing gas to oxidize a solution containing osmium and produce osmium tetroxide gas and a step for introducing the resulting osmium tetroxide gas into a recovery solution; the present invention further relates to a production apparatus therefor.

Abstract: A novel test method for testing for the presence or absence of a predisposition to autistic spectrum disorder or the presence or absence of development of autistic spectrum disorder is provided. The test method includes a test step of determining an amount of at least one of the fatty acid binding proteins FABP3, FABP4, FABP5, and FABP7 in a sample prepared from the living body of a human or determining an expression level of at least one of the FABP3, FABP4, FABP5, and FABP7 genes in the sample.

Abstract: The present invention relates to an agent for activating mammalian sperm and a method for activating sperm by use of the activating agent. More specifically, the present invention relates to a sperm activating agent containing endo-?-galactosidase and/or FGF, which accelerate motility of mammalian sperm, for use in in-vitro fertilization and artificial insemination by husband and a sperm activating method by adding endo-?-galactosidase and/or FGF.

Abstract: The present invention has an object to measure lymphatic pressure with more safety and ease at lower cost. To achieve this, a lymphatic pressure-measuring system 1 includes: a manchette 11 fitted on a vital observation portion; a measurement unit 13 that measures and outputs pressure of the manchette 11; an infrared camera 21 that detects fluorescence emitted from fluorescent dye previously injected into a lymph vessel in the vital observation portion; and an image processing device 22 that generates and displays an image showing a position of the fluorescent dye in the lymph vessel based on a detection result of the infrared camera 21. The infrared camera 21 repeats the detection while the pressure of the manchette 11 decreases from first pressure to block a lymph flow in the vital observation portion to second pressure at restart of the lymph flow. The measurement unit 13 repeats the measurement during the period.

Abstract: By intravenously administering a sedative comprising methyl 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate or a salt thereof to a patient by a dosing regimen including a two-step process disclosed in the present invention, general anesthesia can be safely and promptly induced and maintained.

Abstract: The present invention has an object to measure lymphatic pressure with more safety and ease at lower cost. To achieve this, a lymphatic pressure-measuring system 1 includes: a manchette 11 fitted on a vital observation portion; a measurement unit 13 that measures and outputs pressure of the manchette 11; an infrared camera 21 that detects fluorescence emitted from fluorescent dye previously injected into a lymph vessel in the vital observation portion; and an image processing device 22 that generates and displays an image showing a position of the fluorescent dye in the lymph vessel based on a detection result of the infrared camera 21. The infrared camera 21 repeats the detection while the pressure of the manchette 11 decreases from first pressure to block a lymph flow in the vital observation portion to second pressure at restart of the lymph flow. The measurement unit 13 repeats the measurement during the period.

Abstract: The invention provides an antigen or drug delivery complex containing a complex of an antigen or drug and a cationic molecule, and an anionic molecule encapsulating the same. The antigen or drug delivery complex can be used as a main component of a drug delivery system that delivers various antigens and drugs to a particular cell or organ.

Abstract: A fluorescence detection device comprises: a plurality of light sources that apply an excitation light from an outside of a living body toward fluorescent dye previously injected into the living body; and a plurality of detectors that detect fluorescence emitted from the fluorescent dye by the excitation light, and output the detected fluorescence as an electric signal. The plurality of light sources and the plurality of detectors are arranged in at least one line. At least one detector is placed between two light sources, and at least one light source is placed between two detectors.

Abstract: An autism diagnosis support method and system, and device capable of providing support to early detection and early definite diagnosis on the basis of objective evaluation, are provided by using a conventionally proposed “eye-gaze detection technique”. The method includes: displaying, on a screen of the display portion, a combination image for sequentially displaying at least two images including a predetermined human image (I) and a predetermined non-human image (II); and evaluating an eye-gaze position of the subject by detecting eye-gaze position information on the subject looking at the combination image in use of the eye-gaze detecting unit, then inputting the eye-gaze position information on the subject in an eye-gaze position information storing portion, and comparing, based on an eye-gaze position evaluation algorithm, the eye-gaze position information on the subject with eye-gaze position information on an individual with autism and/or a typically developing individual.

Abstract: A surgery assistance system including a rigid endoscope having a position-orientation detection marker, 3-dimensional (3D) shape measurement device for obtaining data corresponding to a 3D surface of a patient and data corresponding to a 3D surface of the position-orientation detection marker, and computation unit for aligning pre-stored tomographical data of the patient and the data corresponding to the 3D surface of the patient, computing an optical axis of the rigid endoscope on the basis of the data corresponding to the 3D surface of the position-orientation detection marker and a pre-obtained 3D relative position relationship between an actual optical axis of the rigid endoscope and the position-orientation detection marker, for computing a tissue wall in the patient from the 3D tomographical data, and for computing an intersection of the tissue wall and the computed optical axis of the rigid endoscope.